Jade Biosciences, Inc. Common Stock

JBIONASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
14.74 USD
↗ 0.24 (1.66%)AT CLOSE (03:59 PM EDT)
14.75
↗ 0.01 (0.03%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
14.75
↗ 0.01 (0.03%)
🔴Market: CLOSED

Jade Biosciences, Inc. Common Stock (JBIO) trades at $14.74 per share. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics suggest JBIO is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Oct 27, 2026.

Open?$14.52
High?$15.07
Low?$14.36
Prev. Close?$14.50
Volume?652.9K
Avg. Volume?978.6K
VWAP?$14.79
Rel. Volume?0.67x
Bid / Ask
Bid?$13.41 × 500
Ask?$15.98 × 100
Spread?$2.57
Midpoint?$14.70
Valuation & Ratios
Market Cap?937.4M
Shares Out?63.6M
Float?54.1M
Float %?85.0%
P/E Ratio?N/A
P/B Ratio?2.13
EPS?-$1.93
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
55
Market Cap
922.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.jadebiosciences.com
Listed
2025-04-29
Address
221 CRESCENT ST.
WALTHAM, MA 02453
Phone: (781) 312-3013
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
24
Piotroski F-Score?0/9Weak
Altman Z-Score?16.40Safe
Confidence?38%Very Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?20.73%Squeeze Risk
Short Interest?11.2M
Days to Cover?10.9
Free Float54.1M
Avg Daily Volume1.0M
Settlement Date2026-10-15
Financial Health
Current Ratio?14.93Strong
Quick Ratio?14.93Strong
Cash Ratio?3.40Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
71
2.13CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-5.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
6
-28.0%WEAK▾
ROA?
S&P
3
-26.1%WEAK▾
Cash Flow & Enterprise
FCF?$-110213000
Enterprise Value?$830.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist